Aknar Calabrich, MD | Authors

Trastuzumab: Mechanisms of Resistance and Therapeutic Opportunities

October 01, 2008

The human epidermal growth factor receptor 2 (HER2) is a transmembrane receptor with tyrosine kinase activity overexpressed in about 20% to 25% of invasive carcinomas of the breast.